Aestyve
REGENERATE · PN + HA

Aestyve Revibe PNPN

Awakening the skin’s own condition —
a premium PN skin booster

PN 30 mg and hyaluronic acid 10 mg in a single 2 mL prefilled syringe — addressing skin condition and moisture environment together.

Intended use, claims and availability may vary by country regulation and actual product documentation.
KOREAN PREMIUM MEDICAL AESTHETICSAestyve Revibe PN package and prefilled syringe
PN 30 mgPolynucleotide-based skin conditioning
HA 10 mgMoisture retention and a supple feel
2.0 mL1 syringe / box
POLYNUCLEOTIDE

A hydrophilic biopolymer built from
long nucleotide chains

Refined from salmon-derived DNA, PN is a hydrophilic polymer chain formed by many nucleotides linked end to end.

LONG-CHAIN BIOPOLYMER

PN, considered for the skin’s moisture and extracellular matrix environment

Long PN chains interact with water, and are proposed to form a temporary scaffold-like network within the dermis.

Moisture RetentionDesigned around how hydrophilic chains interact with water.
ECM ConditioningSupports the extracellular matrix and the tissue remodelling environment together.
Viscoelastic NetworkThe physical properties of the polymer chain support even distribution through the dermis.
Progressive Skin QualityPoints toward overall improvement in skin condition, including texture and firmness.
01 · STRUCTURE

Long-chain structure

A polymer form in which nucleotide units are repeatedly linked.

02 · HYDROPHILIC

Hydrophilic character

Long chains interact with water to support a moisture-retaining environment.

03 · NETWORK

Three-dimensional network

A scaffold-like network within the dermis has been proposed.

REVIBE FORMULA

PN for recovery,
HA for hydration — in balance

Two core axes of skin condition, in one prefilled syringe.

Long-chain polynucleotide molecular structure
30mg

POLYNUCLEOTIDE

Built on salmon-derived PN, directed at texture, firmness and overall skin condition.

Hyaluronic acid molecule holding water
10mg

HYALURONIC ACID

Supports moisture retention and complements the viscoelasticity and feel of the PN formulation.

REVIBE = PN-based skin conditioning + HA-based moisture support
MECHANISM OF ACTION

A three-step mechanism in which
PN + HA support the dermal environment

PN acts as a hydrophilic polymer scaffold and HA as a moisture-retaining environment, together supporting skin quality.

STEP 01

PN chain dispersion

Long PN chains disperse evenly through the dermal environment.

STEP 02

Hydrophilic scaffold formation

The PN network forms an environment that holds water molecules.

STEP 03

Fibroblast interaction

Supports an environment favourable to cell activity and tissue remodelling.

A proposed mechanism drawn from the literature; it does not represent clinical results for Revibe itself.
WHY REVIBE

What sets Revibe apart runs
from raw material to finished product

A clean supply chain, extraction and purification, and finished-product quality control — connected by a single standard.

01 · SOURCEClean water source and salmon DNA

Salmon-derived PN material

DNA material selected from a controlled supply chain.

02 · TRACEABILITYTraceability system from material to finished product

Material traceability

A control system spanning aquaculture, DNA material and production.

03 · QUALITY CONTROLOperators in sterile gowns inspecting Revibe syringes

Finished-product quality control

Quality criteria carried from material selection through to manufacture.

01 Material selectionSalmon-derived DNA
02 DNA extractionSeparation of non-DNA components
03 PurificationMinimised residual impurities
04 StandardisationControl of PN chain characteristics
05 FormulationPN 30 mg + HA 10 mg
06 Finished-product verificationConfirmation against quality criteria
PHYSIOBALANCE

A precise balance designed around
procedural comfort

Physiological pH and osmolality were tuned with the discomfort typical of PN formulations in mind.

LOW-DISCOMFORT FORMULATION

Physiobalance

Revibe’s formulation approach, directed at a more comfortable procedure from start to finish.

PH BALANCE

Physiological pH balance

Formulated to reduce the irritation that arises from a pH gap with the tissue environment.

OSMOLALITY BALANCE

Osmolality balance

Designed to ease the pain and swelling that follow a concentration gap with body fluid.

‘Reduced discomfort’ is a formulation objective. Actual pain and swelling vary with technique, site and the individual.
PN VS PDRN

Both derive from DNA, but
chain length and physical propertiesdiffer

The terms are often used interchangeably, but PN generally refers to longer polymer chains and PDRN to shorter DNA fragments.

Long polymer chain network of PNPOLYNUCLEOTIDE

PN

Long polymer chain · viscoelasticity · potential network formation

Short DNA fragments of PDRNPOLYDEOXYRIBONUCLEOTIDE

PDRN

Relatively short DNA fragments · studied mainly for biological signalling

Molecular weight ranges and definitions vary with manufacturing process and product specification.
IN THE DERMIS

Targeting the dermal environment,
not the skin surface

After microinjection into the dermis, PN and HA are designed to interact with the moisture and extracellular matrix environment.

Aestyve Revibe PN prefilled syringe
EPIDERMIS
Epidermal tissue in 3D

Epidermis

The stratum corneum and epidermal cells form the barrier that protects skin from external stress.

DERMIS · TARGET AREA
3D dermal tissue with collagen and fibroblasts

Dermis

Home to collagen, elastin and fibroblasts — the target area for PN + HA delivery.

SUBCUTANEOUS
3D subcutaneous tissue with adipocytes and connective tissue

Subcutaneous tissue

Adipocytes and connective tissue form the lower structure that cushions and supports.

The 3D skin layers are conceptual images intended to aid anatomical understanding.
TISSUE RESPONSE

Four stages of tissue change,
from injection to skin conditioning

3D tissue imagery showing how PN and HA disperse within the dermis and interact with the moisture and extracellular matrix environment.

3D image of PN and HA dispersing in the dermis after injection
01 · IMMEDIATE

Immediately after injection

PN and HA disperse finely through the target dermal area, with HA helping form an immediate moisture-retaining environment.

3D image of early hydration response and ECM stabilisation
02 · EARLY RESPONSE

Early response

The early stage in which the hydrophilic polymer network interacts with water and the treated tissue environment settles.

3D image of PN chains interacting with fibroblasts
03 · PN ACTIVATION

Revibe PN activation

Long PN chains interact with the extracellular matrix and fibroblasts, supporting gradual tissue conditioning.

3D image of skin tissue with improved moisture and collagen network
04 · SKIN QUALITY

Skin improvement

Moisture, firmness and texture recover in balance, supporting a denser and healthier skin environment.

Conceptual images visualising a mechanism proposed in the literature. Timing and outcome per stage vary with treatment conditions and the individual.
WHO IS IT FOR?

Skin conditions where
Revibe PN is considered

Rather than a single symptom, clinicians assess overall skin quality — moisture, barrier, texture, firmness — to judge suitability.

01

Sensitive, reactive skin

Skin with recurring redness and discomfort that needs barrier recovery

02

Rough, uneven texture

Skin with fine irregularities and enlarged pores that needs refining

03

Dryness and loss of radiance

Hydration and radiance conditioning for skin that holds little moisture and looks dull

04

Loss of firmness and fine lines

Skin that needs both dermal support and firmness conditioning

05

Maintenance after treatment

Where a stable maintenance plan is needed after skin-quality treatment

These are general examples of skin condition. Whether to treat, and at what depth and volume, must follow clinical diagnosis and approved indications.
SKIN QUALITY SCENARIOS

Direction of change,
by skin condition

Sensitivity, texture and hydration compared on the same area.

BARRIER RESILIENCE

Sensitive skin condition

From recurring redness and reactivity toward an even, comfortable barrier condition.

Skin showing redness and sensitivityBEFORE
Skin with an even, settled barrierAFTER
TEXTURE REFINEMENT

Texture refinement and density

Rough irregularities and prominent pores move toward a smoother, more refined surface.

Rough, uneven skin textureBEFORE
Smooth, refined skin textureAFTER
HYDRATION & RADIANCE

Deep hydration and radiance

From dull, dehydrated skin with fine dry lines toward a supple, luminous finish.

Dehydrated, dull skinBEFORE
Hydrated skin with natural radianceAFTER
The images above illustrate change in skin condition. They are not clinical before-and-after photographs for Revibe, nor a guarantee of results.
PRODUCT SPECIFICATION

Product specification

Aestyve Revibe outer carton
Product nameAestyve Revibe
CategoryTissue-repair biomaterial
Approval no.No. 22-561
CompositionSodium polynucleotide 1.5 mL / 30 mg
Hyaluronic acid 0.5 mL / 10 mg
Total volume2 mL × 1 prefilled syringe
Packaging1 unit per box
Storage1–30 °C, protected from light and direct sunlight
Shelf life3 years from date of manufacture
WHAT'S INSIDE

Package contents

Before opening, check the packaging for damage and confirm the product details, lot number and expiry date. Keep the sterile packaging intact.

Revibe carton with product information and lot marking
01 · CARTON

Outer carton

Product information and lot marking

Sterile-packed Revibe 2 mL prefilled syringe
02 · PREFILLED SYRINGE

Prefilled syringe

2 mL × 1, sterile packaging

Revibe instructions for use
03 · INSTRUCTIONS FOR USE

Instructions for use

Intended use and precautions

Actual contents and labelling may vary by lot and country of supply. The enclosed official instructions for use take precedence.
TREATMENT PROTOCOL

Revibe PN
Clinical treatment guide

Micro point injection into the dermis is the baseline; clinicians adjust for skin thickness, site and patient condition.

01

Assess skin condition

Check pigmentation, pores and redness before treatment.

02

Anaesthesia and sterile preparation

Prepare the Revibe PN syringe and sterile instruments.

03

Intradermal point injection

Set an even treatment map along the facial contour.

04

Soothing and aftercare

Provide soothing care, then explain the precautions.

NEEDLE34G × 4 mm
DOSE / POINT0.02–0.04 mL
POINT INTERVAL3–5 mm
TOTAL VOLUMEUp to 2 mL
Injection plane: intradermal, bevel up. Confirm micro-papule formation and adjust insertion depth to skin thickness.
Reference material for healthcare professionals. The official Revibe IFU and national approval conditions take precedence over this guide.
CLINICAL LITERATURE

Skin-quality outcomes
reported in PN literature

Key clinical findings on improvement in skin-quality measures

SYSTEMATIC REVIEW

9 studies
219 patients

Wrinkles
Texture
Firmness

Promising results for wrinkles, texture and firmness; evidence level low to moderate.

PN VS HA · SPLIT-FACE

Randomized
N=27

HA
PN

Sustained improvement in firmness and hydration was higher in the PN group than the HA group.

PROSPECTIVE COHORT

40 women
3 sessions

Roughness −17.1%
Firmness +39.6%
Radiance +51.1%

Skin roughness −17.1% · firmness +39.6% · radiance +51.1%.

Composition, concentration and technique differ between studies; these figures cannot be read directly as Revibe results.
SAFETY & AFTERCARE

Safe outcomes begin with precise technique
aftercare

If any symptom concerns you, contact the treating clinic immediately.

Same day

Follow clinical guidance on cleansing and make-up, and do not rub the treated area.

2–3 days

Avoid intense exercise, saunas, alcohol and strong heat.

Daily

Keep skin comfortable with sun protection and ample moisturising.

Severe pain or persistent heat, marked swelling or colour change, discharge or fever suggesting infection, or any reaction lasting longer than expected requires clinical review.
AESTYVE REVIBE PN

So your skin
remembers its vitality

PN 30 mg + HA 10 mg · 2 mL / Box
Consult a qualified clinician for a treatment plan suited to your skin.

Aestyve Revibe PN package and prefilled syringe

※ This page is informational material based on the product and related literature.

※ Actual manufacturing and testing items must be confirmed against the manufacturer’s specification and quality documents.

※ Before use, check the official instructions for use (IFU), approval conditions and country regulations.